Kapitalo Investimentos Ltda Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Kapitalo Investimentos Ltda purchased a new stake in Eli Lilly and Company (NYSE:LLYFree Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 523 shares of the company’s stock, valued at approximately $305,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Loomis Sayles & Co. L P lifted its holdings in shares of Eli Lilly and Company by 324.2% during the 3rd quarter. Loomis Sayles & Co. L P now owns 1,069 shares of the company’s stock valued at $574,000 after purchasing an additional 817 shares during the last quarter. Bison Wealth LLC boosted its holdings in Eli Lilly and Company by 13.8% in the third quarter. Bison Wealth LLC now owns 4,504 shares of the company’s stock worth $2,420,000 after acquiring an additional 546 shares in the last quarter. Rathbones Group PLC grew its stake in shares of Eli Lilly and Company by 28.0% during the third quarter. Rathbones Group PLC now owns 72,222 shares of the company’s stock worth $38,793,000 after acquiring an additional 15,803 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Eli Lilly and Company by 17.0% during the third quarter. V Square Quantitative Management LLC now owns 5,760 shares of the company’s stock valued at $3,094,000 after acquiring an additional 837 shares in the last quarter. Finally, Provence Wealth Management Group raised its position in shares of Eli Lilly and Company by 10.3% in the 3rd quarter. Provence Wealth Management Group now owns 2,386 shares of the company’s stock valued at $1,282,000 after purchasing an additional 223 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY traded up $4.29 on Tuesday, reaching $889.30. The stock had a trading volume of 467,839 shares, compared to its average volume of 2,924,406. The business’s 50-day moving average price is $788.10 and its two-hundred day moving average price is $721.39. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $892.20. The company has a market cap of $845.20 billion, a P/E ratio of 130.34, a price-to-earnings-growth ratio of 1.92 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the prior year, the firm posted $1.62 EPS. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Thursday, May 16th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.58%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on LLY shares. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $925.00 to $957.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $787.53.

Get Our Latest Report on Eli Lilly and Company

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the transaction, the insider now directly owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 567,826 shares of company stock worth $475,376,178. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.